Tg Therapeutics Inc (TGTX) financials
Tg Therapeutics revenue and earnings by year
Tg Therapeutics's revenue was $616 million in the fiscal year to December 31, 2025, up 87.3% from the year before. Net income was $447 million, 72.6% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 151.7% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 616 | 329 | 234 | 3 | 7 | 0 | 0 | 0 | 0 | 0 |
| Revenue growth | 87.3% | 40.8% | 8290.0% | -58.4% | 4300.7% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Gross profit | 516 | 291 | 220 | 3 | 6 | — | — | — | — | — |
| Gross margin | 83.7% | 88.3% | 94.0% | 90.5% | 88.2% | — | — | — | — | — |
| Operating income | 123 | 42 | 21 | -218 | -345 | -274 | -169 | -174 | -119 | -79 |
| Operating margin | 20.0% | 12.7% | 8.8% | -7839.0% | -5154.3% | -179996.1% | -111220.4% | -114736.8% | -78100.0% | -51953.3% |
| Net income | 447 | 23 | 13 | -224 | -348 | -279 | -173 | -173 | -118 | -78 |
| Net margin | 72.6% | 7.1% | 5.4% | -8036.3% | -5204.1% | -183803.3% | -113730.9% | -114132.9% | -77944.7% | -51482.2% |
| Diluted EPS | $2.77 | $0.15 | $0.09 | -$1.65 | -$2.63 | -$2.40 | -$1.95 | -$2.30 | -$1.91 | -$1.60 |
| Free cash flow | -25 | -41 | -31 | -176 | -296 | -215 | -133 | -129 | -94 | -62 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TGTX in Markets.
How Tg Therapeutics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $236M | 96.3% |
| License | $4.54M | 1.9% |
| License Revenue | $4.54M | 1.9% |
See also: TGTX valuation and P/E history · TGTX returns
No forecast, no recommendation. This page describes Tg Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.